Gene · 5150
PDE7A: phosphodiesterase 7A
12 sourcesgene-search-2026-11-11-0.2.0
Cite this record
ConductScience Library. PDE7A: phosphodiesterase 7A. Genes, record 5150. Release gene-search-2026-11-11-0.2.0, 11 Nov 2026. https://conductscience.org/library/genes/5150
On this page
Gene
Proteins1
Reviewed human proteins whose Swiss-Prot entry states the gene.
| UniProt entry | Protein | Length | Structures | Gene stated in |
|---|---|---|---|---|
| Q13946 | High affinity 3',5'-cyclic-AMP phosphodiesterase 7A | 482 | 4 | Ensembl, GeneID, HGNC |
Source UniProt
Patents47
Patents whose sequence listing contains this protein's exact sequence. A patent can list a sequence without claiming it.
| Publication | Published | SEQ ID NO | Protein | Source |
|---|---|---|---|---|
| JP 2026004568 A | 2026-01-14 | 57765 | Q13946 | Espacenet |
| EP 4641201 A2 | 2025-10-29 | 12789 | Q13946 | Espacenet |
| EP 4641202 A2 | 2025-10-29 | 6076 | Q13946 | Espacenet |
| JP 2025147176 A | 2025-10-06 | 10169 | Q13946 | Espacenet |
| JP 2025529142 A | 2025-09-04 | 7301 | Q13946 | Espacenet |
| US 12371689 B2 | 2025-07-29 | 7301 | Q13946 | Espacenet |
| JP 2025517969 A | 2025-06-12 | 12789 | Q13946 | Espacenet |
| JP 2025032204 A | 2025-03-11 | 33179 | Q13946 | Espacenet |
| JP 2025028160 A | 2025-02-28 | 10169 | Q13946 | Espacenet |
| KR 1020250017231 A | 2025-02-04 | 6076 | Q13946 | Espacenet |
1 to 10 of 47
See all 47 patentsDrugs4
Drugs a ChEMBL mechanism record says act on the gene's protein, through Open Targets.
| Drug | ChEMBL ID | Mechanism | Action | Source |
|---|---|---|---|---|
| DIPYRIDAMOLE | CHEMBL932 | 3',5'-cyclic phosphodiesterase inhibitor | INHIBITOR | ChEMBL |
| FLAVOXATE | CHEMBL1493 | Phosphodiesterase 7 inhibitor | INHIBITOR | ChEMBL |
| FLAVOXATE HYDROCHLORIDE | CHEMBL1200875 | Phosphodiesterase 7 inhibitor | INHIBITOR | ChEMBL |
| PENTOXIFYLLINE | CHEMBL628 | 3',5'-cyclic phosphodiesterase inhibitor | INHIBITOR | ChEMBL |
Trials135
Trials of those drugs. A trial joins the gene only through a drug that acts on it.
| Trial | Drug | Phase | Results first posted | Source |
|---|---|---|---|---|
| NCT07349472 | PENTOXIFYLLINE | PHASE2 | ClinicalTrials.gov | |
| NCT07315139 | PENTOXIFYLLINE | ClinicalTrials.gov | ||
| NCT07252518 | PENTOXIFYLLINE | ClinicalTrials.gov | ||
| NCT07199504 | DIPYRIDAMOLE | PHASE2/PHASE3 | ClinicalTrials.gov | |
| NCT07088328 | PENTOXIFYLLINE | ClinicalTrials.gov | ||
| NCT07086794 | PENTOXIFYLLINE | EARLY_PHASE1 | ClinicalTrials.gov | |
| NCT07085806 | PENTOXIFYLLINE | ClinicalTrials.gov | ||
| NCT06998628 | PENTOXIFYLLINE | PHASE2 | ClinicalTrials.gov | |
| NCT06986031 | PENTOXIFYLLINE | PHASE2 | ClinicalTrials.gov | |
| NCT06912763 | PENTOXIFYLLINE | PHASE2 | ClinicalTrials.gov |
1 to 10 of 135
See all 135 trialsNIH grants423
NIH grants whose papers are about the gene, through NIH's grant-paper links.
| Grant | Title | PDE7A papers | Newest fiscal year |
|---|---|---|---|
| P30CA008748 | Cancer Center Support Grant | 5 | 2025 |
| UL1TR001863 | Yale Clinical and Translational Science Award | 3 | 2025 |
| P20GM113226 | Hepatobiology and Toxicology COBRE | 2 | 2025 |
| P30DK116074 | Stanford Diabetes Research Center | 2 | 2025 |
| P50AA024337 | The Role of Nutrition in the Development/Progression of Alcohol-Induced Organ Injury | 2 | 2025 |
| R01DK080834 | Inhibition of an Apical cAMP/cGMP Transporter (MRP4) in the Gut Induces Diarrhea | 2 | 2025 |
| I01CX001897 | Genetic of Kidney Disease and Hypertension in MVP II | 1 | 2025 |
| K01AA030083 | Mass Multivariate Derivation and Validation of AUD Biotypes using Developmental Imaging and Genomic Approaches | 1 | 2025 |
| P01CA022443 | Molecular Biology and Genetics of Human Tumor Viruses | 1 | 2025 |
| P20GM113131 | Center of Integrated Biomedical and Bioengineering Research (CIBBR) | 1 | 2025 |
1 to 10 of 423Source NIH's project files
See all 423 nih grantsPapers669
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Both Conserved Aromatic Nature and Critical RNA Motif of Residue 67 in the ToBRFV Movement Protein May Be Essential for Evading Tm-22-Mediated Resistance. | Mol Plant Pathol | 2026 | 42438102 | PubTator, text mining | PubMed |
| Heterocyclic Scaffolds as Therapeutic Agents in Multiple Sclerosis: Mechanisms and SAR Study. | Cent Nerv Syst Agents Med Chem | 2026 | 42393898 | PubTator, text mining | PubMed |
| Tomato Brown Rugose Fruit Virus Evades Tm-22-Mediated Resistance by Avoiding the Induction of Tm-22 Self-Association. | Mol Plant Pathol | 2026 | 41852156 | PubTator, text mining | PubMed |
| Biological implications and therapeutic potential of phosphodiesterase inhibitors: A review. | Medicine (Baltimore) | 2026 | 41790675 | PubTator, text mining | PubMed |
| Single-Cell Transcriptomic Profile Associated with Sub-Subtype A6 and CRF63-02A6 HIV-1 Strain Infection. | Viruses | 2026 | 41754547 | PubTator, text mining | PubMed |
| Family-Wide Dysregulation of Phosphodiesterases Alters cAMP/cGMP Microdomains in Thoracic Aortic Aneurysm. | J Cardiovasc Dev Dis | 2026 | 41590850 | PubTator, text mining | PubMed |
| Integrative multi-omics analyses identify key genes and elucidate bidirectional regulatory mechanisms in thyroid dysfunction. | PLoS One | 2026 | 41570039 | PubTator, text mining | PubMed |
| Advanced molecular tools for surveillance and management of tobamoviruses. | Front Plant Sci | 2025 | 41613398 | PubTator, text mining | PubMed |
| Pan-Cancer Analysis of Cyclic Nucleotide Phosphodiesterases (PDEs) Expression, Variation, and Prognostic Significance. | ACS Omega | 2025 | 41476499 | PubTator, text mining | PubMed |
| Expanding disease resistance: engineered NLRS for broad-spectrum protection. | Mol Hortic | 2025 | 41276870 | PubTator, text mining | PubMed |
1 to 10 of 669
See all 669 papersSources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this gene from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/genes/v1/5150
GET https://conductscience.org/api/genes/v1/5150/patents?page=2